OTCM
DIUXF
Market cap228mUSD
, Last price
Name
Diaceutics PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This platform features DXRX data solutions, providing access to extensive diagnostic testing data pipelines from a broad network of laboratories, including real-time DXRX signal alerts, lab and physician mapping, and a testing dashboard. The DXRX platform also hosts a marketplace where laboratories, pharmaceutical firms, and diagnostic companies can connect to collaborate on precision medicine diagnostics. Diaceutics further provides DXRX Patient Journey, a tool for pharmaceutical clients to conduct detailed longitudinal analyses of individual patient biomarker testing paths, helping identify opportunities for earlier intervention and treatment. DXRX Lab Benchmarking allows laboratories to sharpen their competitive edge by comparing their key criteria against industry counterparts, encompassing metrics such as disease focus, testing methodologies, market share, turnaround times, and their standing as leaders in specific diagnostic fields. The DXRX Test Reimbursement service assists pharma clients in funding novel companion diagnostics, thereby shortening the time required for their widespread adoption. Furthermore, DXRX Test Signal delivers immediate notifications of testing events, empowering pharmaceutical clients to swiftly identify therapeutically actionable patients. Beyond the platform, Diaceutics furnishes services for diagnostic landscape analysis, strategic planning, implementation, and ongoing tracking, alongside expert consulting tailored to precision medicine diagnostics. Its extensive service portfolio also covers test standardization, quality evaluations, optimization of test reports, technical laboratory support, assistance with test access and reimbursement, laboratory training, and various educational resources.
Related entities
Subsidiaries
DIACEUTICS IRELAND LIMITED
Key people
Peter Keeling
Non-Executive Chairman of the Board · since 2024
Sandra Blake
Chief People Officer · since 2024
Madeline Brown
Vice President, Chief of Staff · since 2024
Kerri Donaldson
Vice President - Customer Operations · since 2024
Gosia Leitch
Vice President - Engagement Solutions · since 2024
Amie Mcneice
Vice President - Marketing · since 2024
Scott Phillips
Vice President - Real-World Data · since 2024
Ken Ruppel
Vice President - Scientific and Medical Services · since 2024
Marianna Sciortino
Vice President - Sales · since 2024
Lauren Dewitt
Executive Vice President, Legal, General Counsel, Group Company Secretary · since 2025
Jordan Clark
Chief Data Officer, Executive Director · since 2024
Ryan Keeling
Chief Executive Officer, Executive Director · since 2024
Nick Roberts
Chief Financial Officer, Executive Director · since 2022
Non-Executive Director · since 2024
Senior Independent Non-Executive Director · since 2024
Headquarters & legal address
First Floor, Building Two
Dataworks At Kings Hall Health & Wellbeing Park
Belfast, BFS BT9 6GW
GB
Dataworks At Kings Hall Health & Wellbeing Park
Belfast, BFS BT9 6GW
GB
Previous name
DIACEUTICS LTD
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||